30 closest matches · ranked by relevance
Lymphoceles · Prostate Cancer
Primary: Incidence of Lymphoceles — 10; 12; 104; 102 participants — p=0.412
Lymph Node Dissection · Lymphoedema · Lymphocoele
Primary: Postoperative Draining Time — 31; 32 days
Seroma
Primary: Number of Participants With Seroma Formation — 2; 8 participants — p=0.022
Malignant Melanoma · Carcinoma, Squamous Cell
Primary: Post-operative Wound Drainage. — 892.5; 762.5; 565; 590 ml — p=0.704
Lymphoceles Following Pelvic Lymph Node Dissection
Primary: Number of Participants With Incidence of Lymphocele Formation — 1 Participants
Lymph Node Resection
Primary: Percentage of Participants With Post-Operative Seroma Formation Over Time as Determined at Hospital Discharge — 2.63 percentage of participants
Lymphedema · Edema
Primary: Change in Limb Volume — -15; -202 mL
Breast Cancer · Axillary Lymph Node Dissection
Primary: Number and Prevalence of Metastases of Blue Nodes in the ALND Specimen (Nodes Draining the Breast). — 0 participants
Breast Cancer With Chronic Lymphedema
Primary: Lymphedema as Measured at Baseline and at 6 Weeks — 4.74; 4.82; 4.29; 4.76 cm
Secondary Lymphedema
Primary: Assessing a Change in Bioimpedance Spectroscopy (BIS) — 1.3; 1.8 Change of score on a scale
Lymphedema · Breast Cancer
Primary: Number of Participants With Successful Assessment of Lymphedema by Multiple Frequency Bioimpedance Spectroscopy — 19; 21; 22 participants
Peritoneal Dialysis · Hypervolemia · VEGF Overexpression
Primary: Association Between Number of Kerley B Lines by Ultrasound and Serum VEGF-C Level (pg/ml) by Enzyme-linked Immunosorbent Assay — 0.29; 0.25; 0.33 ng/ml — p=0.039
Breast Cancer · Melanoma
Primary: Concordance of Blue Dye and Lymphoseek — 1.0000 Proportion of Lymph Nodes
Lymphangioleiomyomatosis · Lymphangiomyomas · Pleural Effusions
Primary: Number of Participants With a Reduction in Total Tumor Volume of at Least 20%. — 0 Participants
Coronary Bypass Graft Stenosis of Autologous Vein
Primary: Early Complications of Vascular Zone — 1; 4; 15; 5 participants — p=0.05
Lymphedema
Primary: Change in Volume Ipsilateral Lymphedema in Arm — -161.0; -372.8 mL — p=0.0658
Breast Cancer · Melanoma
Primary: Concordance of Blue Dye and Lymphoseek — 0.9767 Proportion of Lymph Nodes
Cervical Squamous Cell Carcinoma · Adenosquamous Carcinoma · Adenocarcinoma
Primary: Overall Survival Rate
Cholelithiasis
Primary: Number of Participants With Subhepatic Collection at Ultrasonographic Examination — 45; 46 Participants
Abdominal Abscess · Pelvic Abscess
Primary: Percentage of Patients Requiring Surgical Debridement for a Persistent Abscess Within 30 Days Following Initial Drainage — 3; 7 participants
Lymphedema
Primary: Part 1: Count of Participants Able to Complete Ketoprofen Treatment — 50 Participants
Lymphedema
Primary: Number of Participants Who Were Lymphedema-free 18 Months After Randomization — 114; 135 Participants
Lymphatic Malformations
Primary: Number of Participants With Clinical Success at 1 to 6 Months Post-Therapy as Assessed by Imaging — 57 Participants
Healthy Subject
Primary: Change in Hand Volume Following Tourniquet Use — 15.0; 12.1; 12.5; 7.9 mL
Cancer of the Urinary Tract
Primary: Number of Participants With Pathologically Proven Lymph Node Metastasis — 1 participants
Lymphedema · Surgery · Breast Cancer
Primary: Number of Cases Where Lymphatics Were Visualized by Blue Dye Versus by ICG Using the OnLume Imaging System — 5; 9 Participants
Lymphedema, Secondary · Lymphedema of Upper Limb
Primary: Recruitment Rates — 32.5; 37.5 rate of recruitment
Bladder Cancer
Primary: Median Yield of Robot Assisted and Second Look Open Pelvic Lymph Node Dissection to Compare the Lymph Node Yield Achieved — 43; 4 Nodes (Node Yield)
Acute Cholecystitis · Empyema of Gallbladder · Abscess of Gallbladder
Primary: Complication — 7; 7 participants
Breast Cancer Related Lymphedema · Covid19
Primary: COVID-19 Vaccination on Contralateral vs Ipsilateral Arm — 432; 435; 331; 122 Participants